肝癌诊疗新进展:指南引领规范创新赋能精准  

New progress in liver cancer diagnosis and treatment:guidelines lead standardization,innovations empower precision

作　　者：樊嘉[1] 高强[1] Fan Jia;Gao Qiang(Liver Cancer Institute,Zhongshan Hospital,Fudan University,Shanghai 200032,China)

机构地区：[1]复旦大学附属中山医院复旦大学肝癌研究所,上海200032

出　　处：《中华消化外科杂志》2024年第2期197-203,共7页Chinese Journal of Digestive Surgery

基　　金：国家自然科学基金(82394450)。

摘　　要：原发性肝癌是严重威胁我国人民生命健康的重大疾病。免疫治疗联合靶向药物(以下简称靶免联合治疗)在肝癌中的突破性进展开创了肝癌治疗新时代。当前,以免疫治疗为基础的联合治疗已经贯穿于肝癌全线治疗,特别是近期在新辅助治疗、转化治疗、术后辅助治疗、联合局部治疗等方面的探索取得诸多成效,进一步提高了患者预后。尽管如此,无论是靶免联合治疗还是双免疫治疗,总体应答率仍有待进一步提高,精准选择有效人群仍未实现。尤其是原发性耐药以及获得性耐药问题更是目前迫切需要解决的重大临床和科学问题,肿瘤基础理论的突破、治疗新靶点的鉴定、制药工业的创新研发、敏感耐药机制的解析等各方面齐头并进显得尤为关键。笔者深入阐述肝癌临床和转化治疗研究创新进展,以期为学界开展相关研究提供参考。Primary liver cancer represents a major health concern in China.The combination of targeted therapy with immunotherapy has initiated a new era in liver cancer treatment.Currently,immunotherapy-based combinational therapies are widely applied across all stages of liver cancer care,with notable improvements in neoadjuvant therapy,conversion therapy,postoperative adjuvant therapy,and locoregional treatments.These advancements have significantly improved patient outcomes.However,whether it is combination of targeted therapy with immunotherapy or dual immunotherapy for liver cancer,the overall response rate still needs to be further improved.Another crucial challenge remains in accurately selecting patients who will stand to benefit from these treatments.Importantly,tackling both primary and acquired drug resistance also presents an urgent and critical clinical and scientific issue in this field.Advancements in understanding tumor biology,discovering novel therapeutic targets,fostering pharmaceutical innovation and development,and decoding the mechanisms of drug sensitivity and resistance are all equally vital for the future breakthroughs in liver cancer treatments.The authors elaborate on the innovative progress of clinical and translational therapy research for liver cancer,in order to provide reference for the academic community to carry out related research.

关 键 词：肝肿瘤 靶向治疗 免疫治疗 耐药 预后 

分 类 号：R735.7[医药卫生—肿瘤]